Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Anti-macular degeneration agents.

Michelle Rothen1, Eric Jablon, Gerardo Monares

  • 1Carolina Foundation for Macula Research and Education, Charleston, SC 29414, USA.

Ophthalmology Clinics of North America
|November 30, 2005
PubMed
Summary

Novel anti-VEGF therapies show promise for treating ocular neovascular diseases like wet age-related macular degeneration (NVAMD). These targeted biologics offer effective and safe treatment options with minimal retinal damage.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

STELLATE UNILATERAL NONHEREDITARY IDIOPATHIC FOVEOMACULAR RETINOSCHISIS: A MULTIMODAL IMAGING ANALYSIS AND CASE REPORT.

Retinal cases & brief reports·2020
Same author

Functional and anatomical outcomes for intravitreal bevacizumab treatment of choroidal neovascularization in a patient with angioid streaks.

Retinal cases & brief reports·2014
Same author

Metabolic control and diabetic retinopathy.

Current diabetes reviews·2009
Same author

Diabetic retinopathy and angiogenesis.

Current diabetes reviews·2009
Same author

Cross-sectional associations of C-reactive protein with vascular risk factors and vascular complications in the DCCT/EDIC cohort.

Journal of diabetes and its complications·2008
Same author

Intravitreal triamcinolone for the treatment of diabetic macular edema.

Current diabetes reviews·2008

Area of Science:

  • Ophthalmology
  • Vascular Biology
  • Pharmacology

Background:

  • Ocular neovascular diseases, such as neovascular age-related macular degeneration (NVAMD), pose significant vision loss risks.
  • Current treatments aim to inhibit pathological blood vessel growth.

Purpose of the Study:

  • To evaluate the efficacy and safety of novel anti-VEGF therapies for ocular neovascular diseases.
  • To explore the potential of these new biologics as standalone or combination treatments.

Main Methods:

  • Review of preclinical and clinical data on novel anti-VEGF agents.
  • Analysis of treatment efficacy, safety profiles, and mechanisms of action.

Main Results:

  • Novel anti-VEGF therapies demonstrate promising efficacy and safety in treating NVAMD.

Related Experiment Videos

  • These agents offer targeted approaches with minimal damage to retinal tissue when administered correctly.

    • Conclusions:

    • Novel anti-VEGF biologics represent a significant advancement in treating ocular neovascular diseases.
    • Biotherapeutic agents are expected to play a crucial role in managing choroidal neovascularization in the future.